CarNow, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
CarNow, Inc. - overview
Established
2014
Location
Atlanta, GA, US
Primary Industry
Retail
About
Based in Oxford, UK, and founded in 2017 by co-founders Tom McCarthy and Stuart Hughes, Pathios Therapeutics Limited operates as a biotechnology company that engages in research and development of immunotherapy approach for cancers. In April 2024, Pathios Therapeutics Limited raised USD 25 million in Series B funding led by Bristol-Myers Squibb Company, with participation from Canaan Partners and Brandon Capital Partners. Pathios Therapeutics Limited provides oncology and immunology solutions for cancer treatment through targeting the acid sensing GPCR, GPR65. The company’s product, PTT-4256, is an orally bioavailable, highly potent, and selective GPR65 inhibitor, designed to reverse the immunosuppressive effects of acidic pH in the TME.
It developed human genetics-led research, transcriptomics, and cellular immunology with insights into the underlying causal biology of immune cell dysfunction in cancer. The company's research extends beyond cancer, exploring the potential of GPR65 modulation in other immunological diseases like Inflammatory Bowel Disease and Multiple Sclerosis.
Current Investors
Sigma Prime Ventures, Runway Growth Capital
Primary Industry
Retail
Sub Industries
Automobile Dealerships, Social Networking & Communication Platform, Customer Relationship Management
Website
www.carnow.com
Verticals
Mobile Apps
Total Amount Raised
Subscriber access only
CarNow, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.